Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Citalopram
Drug ID BADD_D00475
Description Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
Indications and Usage For the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label].
Marketing Status Prescription
ATC Code N06AB04
DrugBank ID DB00215
KEGG ID D07704
MeSH ID D015283
PubChem ID 2771
TTD Drug ID D0Y5DO
NDC Product Code 69097-823; 42806-020; 70518-0561; 43063-385; 43353-112; 70518-2228; 65162-054; 67046-102; 71610-092; 0456-4020; 50090-5170; 69097-824; 68788-7899; 70518-2617; 43063-063; 70934-539; 65162-052; 54458-980; 69097-822; 70518-2553; 0054-0062; 52427-691; 60429-174; 67046-106; 76282-629; 61919-390; 76282-628; 50090-5172; 54458-889; 70518-2601; 70518-2671; 54458-981; 0378-6233; 71335-0541; 60429-173; 71610-412; 63850-3616; 65162-053; 0378-6231; 0456-4010; 42806-021; 76282-206; 68071-3034; 67046-101; 70518-0449; 60429-175; 70934-397; 43353-208; 50090-5175; 63629-6761; 0456-4040; 61919-389; 76282-208; 71610-422; 80425-0093; 76282-207; 0378-6232; 43353-091; 42806-019
Synonyms Citalopram | Cytalopram | Citalopram Hydrobromide | Lu-10-171 | Lu10171 | Seropram | Celexa
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 59729-33-8
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Clonus17.02.05.0020.000250%Not Available
Coagulopathy01.01.02.001--Not Available
Coarctation of the aorta24.04.01.002; 03.07.08.0010.000033%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.000208%Not Available
Colitis07.08.01.001--
Collagen disorder15.06.01.005; 10.04.04.002--Not Available
Colon cancer07.21.01.001; 16.13.01.001--Not Available
Coma17.02.09.0010.001250%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.002130%Not Available
Conduction disorder02.03.01.0080.000333%
Confusional state19.13.01.001; 17.02.03.0050.003083%
Congenital central nervous system anomaly17.19.01.003; 03.10.02.0040.000417%Not Available
Congenital cystic kidney disease16.27.01.002; 20.01.04.006; 03.06.01.0030.000083%Not Available
Congenital megacolon07.02.05.005; 03.04.04.0020.000250%Not Available
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.000083%Not Available
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Conversion disorder19.24.01.001--Not Available
Convulsion neonatal18.04.04.003; 17.12.03.0170.000167%Not Available
Coordination abnormal17.02.02.0040.000292%Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.001--
Creatinine renal clearance decreased13.13.01.0130.000083%Not Available
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Croup infectious22.07.03.023; 11.01.13.0200.000033%Not Available
Crying08.01.03.005; 19.04.02.002; 17.02.05.013; 12.02.11.0010.000750%Not Available
Cryptorchism21.15.01.001; 05.05.02.002; 03.03.01.0010.000958%Not Available
Cushing's syndrome14.11.01.007; 05.01.01.001; 24.08.04.001; 19.07.03.0020.000033%Not Available
Cyanosis02.01.02.002; 24.03.01.007; 22.02.02.0070.000333%
Cystic fibrosis22.03.01.015; 07.18.03.001; 03.16.01.0020.000022%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 37 Pages